Tags:AdTechEngineeringGrowthHealthTechMarketplaceMaterialsPlatformProductSpaceTechnology
Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
Member count: 51-200
Total raised: $49M
Founded date: 2000

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
24.07.2012-$49M-finsmes.co...

Mentions in press and media 14

DateTitleDescriptionCategoryAuthorSource
29.06.2016The biotec...There was a time af­ter the 20...FinancingJohn Carro...endpts.com...
05.12.2014Histogenic...Histogenics Corporation, a Wal...USA-finsmes.co...
17.11.2014Histogenic...Histogenics set the per-share ...-Brad Perri...massdevice...
08.10.2014Histogenic...Histogenics filed for an initi...-Alexander ...massdevice...
26.07.2012Histogenic...Histogenics Corporation, a Wal...funding U...-finsmes.co...
24.07.2012Fundraisin...Money raised: $49 million in s...--medcitynew...
24.07.2012UPDATE: Hi...Histogenics said it raised ano...-MassDevice...massdevice...
24.07.2012Histogenic... WALTHAM, MA, Regenerative me...--vcnewsdail...
12.10.2011Whistleblo...A Northwestern University card...-MassDevice...massdevice...
30.05.2011Orthopedic...Histogenics has one product, a...--medcitynew...
Show more